Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 3/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915775 | 0.89 | SMPD1 (0.47) | SMPD1PTPN11 | |
| SCHEMBL14507234 | 0.86 | LMNA (0.52) | TP53TSHRMAPT | |
| SCHEMBL2917087 | 0.85 | CYP19A1 (0.46) | MAPTSMPD1PTPN11 | |
| SCHEMBL2056260 | 0.83 | CREBBP (0.51) | MAPTSMPD1PTPN11 | |
| SCHEMBL13790359 | 0.83 | MAPT (0.68) | TP53TSHRPLA2G4BMAPTRARB | |
| SCHEMBL14507238 | 0.82 | LMNA (0.54) | TSHRMAPT | |
| SCHEMBL2948416 | 0.82 | LTC4S (0.48) | SMPD1PTPN11 | |
| SCHEMBL17203727 | 0.81 | TP53 (0.74) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL4518941 | 0.81 | SMPD1 (0.61) | PLA2G4BSMPD1 | |
| SCHEMBL2056261 | 0.80 | PTPN11 (0.47) | MAPTSMPD1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286215-A1 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | 2010-11-11 | — | — | US | disclosed |
| EP-2185504-A2 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009030887-A2 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286215-A1 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | LTC4S, LTB4R2, LTB4R | TP53 2053/4885TSHR 2434/4885PLA2G4B 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.